Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Holy Stone Healthcare Co., Ltd. plant passes GMP assessment


Sunday, 16 Feb 2014 07:52pm EST 

Holy Stone Healthcare Co., Ltd:Shinchu-based plant passed good manufacturing practice (GMP) assessment.New drug IBD98-M will be developed and produced at plant. 

Company Quote

36.58
-1.92 -4.99%
30 Apr 2015